In 2,749 adults with type 2 diabetes and high heart risk, Lilly's pill had fewer heart events and less low blood sugar, but GI side effects hit 62% of users.
Recap by typeshit. Full story at Pharmacy Times.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
The advisory committee voted to return six peptides barred in 2023, over FDA staff objections. The author argues the GLP-1 shortage proved compounders can deliver.
On Longevity.Technology's podcast, the two contrast well-studied GLP-1 drugs with thinly tested compounds and discuss gray-market risks and testing.
Loading…